PharmaDrug’s SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine

Apr 16, 2024

Victoria’s Chiral Labs to lead development of novel cocaine manufacturing process   Toronto, Ontario – April 16, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty...

PharmaDrug’s SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine

Mar 13, 2024

Toronto, Ontario – March 13, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC PINK: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of...

PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman

Feb 27, 2024

Toronto, Ontario – February 27, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of...

PharmaDrug’s Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies

Feb 14, 2024

Company to pursue regulatory filing for Phase I/II clinical study   Toronto, Ontario – February 14, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company...

PharmaDrug CEO Provides Vision for Securedose Acquisition

Dec 13, 2023

Toronto, Ontario – December 13, 2023 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of...

PharmaDrug Inc. Closes Acqusition of Securedose Synthetics

Nov 7, 2023

Toronto, Ontario – November 7, 2023 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company”), is pleased to announce that it has closed the previously announced acquisition (see press release dated October 27,...